BIO-RAD LABORATORIES, INC. (BIO-B) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-30

Key Insights

Bio-Rad announced Q1 2026 financial results on April 30, 2026, with earnings materials and supplemental presentation posted to the investor relations website for stakeholder review.
The filing indicates routine earnings disclosure without mention of material agreements, executive changes, or significant business developments, suggesting a standard quarterly reporting event.
Both Class A and Class B common stocks are registered on the NYSE, with the company maintaining dual-class share structure typical of founder-controlled life sciences firms.

Want the newest filings?

This analysis covers the filing from 2026-04-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-24

The company successfully increased its equity incentive pool by 335,000 shares and extended the plan expiration to March 2036, indicating confidence in long-term growth and ability to attract/retain talent through equity compensation.
Strong stockholder support for compensation practices with 96.2% approval of the advisory vote on executive compensation, suggesting alignment between management and shareholders on pay practices.
The dual class capital structure proposal was decisively rejected with 78.8% voting against, demonstrating shareholder preference for one-share-one-vote governance despite management's apparent support for maintaining dual classes.
All six director nominees were elected with substantial majorities, with Class A directors (Litherland and Pinkston) receiving 88.3% and 88.8% support respectively, reflecting strong board continuity and shareholder confidence.

Filed: 2026-02-19

Sartorius AG, in which Bio-Rad Laboratories has an investment, reported strong financial results for the year ended December 31, 2025, with increases in sales revenue, gross profit, EBIT, and net profit.
Sartorius AG's cash flow from operating activities was robust at €837.0 million, indicating the company's ability to generate cash from its operations.
Bio-Rad's investment in Sartorius AG continues to be a significant contributor to its financial performance, as evidenced by the detailed financial information provided in the 8-K filing.

Filed: 2026-02-12

The company announced its financial results for the quarter ended December 31, 2025, which could provide insight into its recent performance.
The company posted supplemental earnings materials on its website, which may contain additional details on the quarterly results.
The filing does not mention any material agreements, leadership changes, or earnings surprises, suggesting a routine quarterly report.

Other reports for BIO-RAD LABORATORIES, INC.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.